See more from the Santa Rosa Press-Democrat: Firefighters say this medicine could save their lives
Back to Journals Drug Design, Development and Therapy Volume 20 GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation Received 1 April 2026 Accepted for publication 2 June 2026 Published 12 June 2026 Volume 2026:20 613616 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Professor Anastasios Lymperopoulos Pengpeng Li, Yangyang Gao, Wei Liu Department of Neurosurgery, Xian Aerospace Hospital of Northwest University, Xian, Shanxi, 710000, Peoples Republic of China Correspondence: Pengpeng Li, Email [email protected] Wei Liu, Email [email protected] Abstract: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity
It also breaks down muscle tissue, especially when protein intake drops alongside overall calories
Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the receptor every GLP-1 compound targets), MC4R (central to satiety and energy balance), and TCF7L2 (tied to glucose homeostasis) describe your baseline metabolic terrain
Fiber (particularly soluble fiber like psyllium) has its own evidence base for constipation management and is often used alongside probiotics
S.TangM.et al (2018)
